Bicuspid Aortic Valve Disease  by Siu, Samuel C. & Silversides, Candice K.
B
c
m
p
c
d
c
d
r
t
b
B
a
a
r
a
d
l
F
C
A
C
o
(
C
O
2
Journal of the American College of Cardiology Vol. 55, No. 25, 2010
© 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
PSTATE-OF-THE-ART PAPER
Bicuspid Aortic Valve Disease
Samuel C. Siu, MD, SM,*† Candice K. Silversides, MD, SM†
London and Toronto, Ontario, Canada
Bicuspid aortic valve (BAV) disease is the most common congenital cardiac defect. While the BAV can be found
in isolation, it is often associated with other congenital cardiac lesions. The most frequent associated finding is
dilation of the proximal ascending aorta secondary to abnormalities of the aortic media. Changes in the aortic
media are present independent of whether the valve is functionally normal, stenotic, or incompetent. Although
symptoms often manifest in adulthood, there is a wide spectrum of presentations ranging from severe disease
detected in utero to asymptomatic disease in old age. Complications can include aortic valve stenosis or incom-
petence, endocarditis, aortic aneurysm formation, and aortic dissection. Despite the potential complications,
2 large contemporary series have demonstrated that life expectancy in adults with BAV disease is not shortened
when compared with the general population. Because BAV is a disease of both the valve and the aorta, surgical
decision making is more complicated, and many undergoing aortic valve replacement will also need aortic root
surgery. With or without surgery, patients with BAV require continued surveillance. Recent studies have improved
our understanding of the genetics, the pathobiology, and the clinical course of the disease, but questions are
still unanswered. In the future, medical treatment strategies and timing of interventions will likely be refined.
This review summarizes our current understanding of the pathology, genetics, and clinical aspects of BAV dis-
ease with a focus on BAV disease in adulthood. (J Am Coll Cardiol 2010;55:2789–800) © 2010 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.12.068r
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vicuspid aortic valve (BAV) disease (Fig. 1) is the most
ommon congenital heart defect, with a prevalence esti-
ated between 0.5% and 2% (1–5). There is a male
redominance of approximately 3:1. In adulthood, compli-
ations are common (6,7), and therefore, the burden of
isease from BAV disease is more significant than any other
ongenital cardiac lesion. Despite its importance, our un-
erstanding of BAV disease is incomplete and questions
emain unanswered about this common condition. Al-
hough much of the original focus centered on the abnormal
ileaflet valve, the disease is significantly more complex.
AV disease is not only a disorder of valvulogenesis, but
lso represents coexistent aspects of a genetic disorder of
orta and/or cardiac development. This review will summa-
ize our current understanding of the pathology, genetics,
nd clinical aspects of BAV disease with a focus on BAV
isease in adulthood.
The bicuspid valve is typically made of 2 unequal-sized
eaflets. The larger leaflet has a central raphe or ridge that
rom the *Division of Cardiology, University of Western Ontario, London, Ontario,
anada; and the †University of Toronto, Toronto Congenital Cardiac Centre for
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f Canada (NA 5927, NA 5662, T6085) and Canadian Institutes of Health Research
53030, 93722). Dr. Siu is the recipient of the Ramsay Gunton Professorship in
ardiology, Schulich School of Medicine and Dentistry, University of Western
ntario, Canada.t
Manuscript received April 20, 2009; revised manuscript received November 6,
009, accepted December 17, 2009.esults from fusion of the commissures, and these fused
ommissures are susceptible to disruption as occurs with
alloon valvuloplasty. The morphologic patterns of the
ileaflet valve vary according to which commissures have
used, with the most common pattern involving fusion of
he right and left cusps. Fusion of the right and left coronary
usps is associated with coarctation of the aorta. Fusion of
he right and noncoronary cusps is associated with cuspal
athology. Rarely, the leaflets are symmetrical or there is no
aphe (“pure” bicuspid valve). A number of classifications
ave been used that pertain to the orientation of the leaflets
2,8–10).
Nonvalvular findings occur in up to 50% of adults with
AV. The most common abnormality is dilation of the
horacic aorta. In 1928, Abbott (11) first described the
ssociation between BAV and aortic disease, and in 1972,
cKusick (12) reported on the association between BAV
nd Erdheim cystic medical necrosis. Whereas some
hanges may be secondary to flow dynamics, so-called
ost-stenotic dilation, more recent studies have shown that
tructural abnormalities occur at the cellular level indepen-
ent of the hemodynamic lesion (13–16). The thoracic aorta
hows decreased fibrillin, elastin fragmentation, and apo-
tosis (17–19). Deficient fibrilin-1 results in smooth muscle
ell detachment, matrix disruption, and cell death (17).
ncreases in matrix metalloproteinases (endopeptides in-
olved in cell matrix turnover) are thought to contribute to
his process (18,20,21). The pulmonary trunk shows some
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Bicuspid Aortic Valve Disease June 22, 2010:2789–800similar structural abnormalities
in patients with BAV, but the
clinical significance of this find-
ing is less clear (18,22).
BAV and associated thoracic
aortic aneurysms are thought to
be manifestations of a single gene
defect (23). BAV disease is also
known to coexist with other con-
genital vascular defects; the most
ommon of which is coarctation of the aorta. Of patients
ith coarctation, approximately 50% to 75% have BAV
24). BAV is also associated with and genetically related to
eft-sided lesions such as hypoplastic left heart syndrome
25–27). There are a number of syndromes whose cardiac
nvolvement includes BAV and left-sided obstructive le-
ions: Shone’s syndrome with multiple left-sided lesions of
nflow and outflow obstruction (28), Williams syndrome
ith supravalvular stenosis, and Turner syndrome with
oarctation of the aorta (29). Other congenital lesions that
ave been associated with BAV include ventricular septal
efects, patent ductus arteriosus, or atrial septal defects,
uggesting a more global disorder of cardiac development as
basis for the disorder. Finally, some reports have suggested
nvolvement of the coronary arteries including single coro-
aries or reversal of coronary dominance (30–32).
Cardiac and valve morphogenesis occur early in fetal
evelopment. Initially, the extracellular matrix thickens and
orms an endocardial cushion that ultimately develops into
he 4 cardiac valves. The actual events that lead to abnormal
alvulogenesis and the formation of a BAV are not known.
arlier theories proposed that abnormal blood flow across
he developing valves would result in failure of cusp sepa-
ation. More recent theories involve cell migration, signal-
ng pathways, and genetic susceptibility. Abnormal neural
rest migration resulting in fusion of valve cushions has been
uggested as a possible explanation by which BAV disease
evelops in humans (33–36). Aortic aneurysms, cervicoce-
halic aneurysm, and intracranial aneurysms, all of neural
rest origin, are reported in the BAV population (37,38).
thers have suggested the extracellular matrix proteins play
pivotal role in valvulogenesis and BAV development.
ndothelial nitric oxide is important in vascular and valve
ormation, and knockout mice without endothelial nitric
xide synthase can develop BAV (39).
enetics
here have been a number of reports of familial clustering of
AV disease (40,41). Glick and Roberts (41) reported a
revalence of aortic valve disease of 24% in families with more
han 1 person with aortic disease, suggesting a Mendelian
attern of inheritance. However, determining the genetics of
AV is complex, and recent studies have demonstrated that
Abbreviations
and Acronyms
ACC  American College of
Cardiology
AHA  American Heart
Association
BAV  bicuspid aortic
valveAV is likely due to mutations in different genes withissimilar patterns of inheritance (42). To date, only a few of
hese pathways have been identified. Mutations in the signal-
ng and transcriptional regulators NOTCH1 (gene map locus
q34.3) result in abnormal aortic valve development (BAV)
nd later to de-repression of calcium deposition (43,44). This
mportant finding provides linkage between the genetic abnor-
ality, abnormal morphogenesis, and subsequent disease pro-
ression. Regions 18q, 5q, and 13q are reported to contain
enes responsible for BAV and/or associated cardiovascular
alformations (45). The region 10q contains the ACTA2 gene,
hich encodes for smooth muscle alpha-actin (ACTA2), and
utation in this gene can result in thoracic aneurysm and, in
ome instances, BAV (46). The ubiquitin fusion degradation
-like gene, expressed in the outflow tract during embryogen-
sis is down-regulated in BAV tissue when compared with
rileaflet valve tissue. Although more studies are required
efore genetic screening will have a role, clinical studies have
eported a 9% prevalence of BAV in first-degree relatives of
atients with BAV (42,47), and based on this data and expert
pinion, the current American College of Cardiology (ACC)/
merican Heart Association (AHA) adult congenital heart
isease guidelines suggest echocardiographic screening for
AV in first-degree relatives of patients with BAV (48).
iagnosis
uscultatory findings include an ejection sound best heard at
he apex. There may be associated murmurs of aortic stenosis,
ncompetence, or coarctation of the aorta when these lesions
re present. In the current era, transthoracic echocardiograms
sually confirm the diagnosis. When adequate echocardio-
Figure 1 Schematic of the Bicuspid Aortic Valve
Depicted is the abnormal bicuspid valve. Other aspects of the disease include
abnormalities of the media in the proximal ascending aorta with resultant dila-
tion of the ascending aorta, abnormalities in the media of the proximal pulmo-
nary artery, and, in some cases, variations in coronary anatomy. Figure
illustration by Rob Flewell.
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June 22, 2010:2789–800 Bicuspid Aortic Valve Diseaseraphic images are obtained, sensitivities and specificities of
2% and 96% are reported for detecting BAV anatomy. The
chocardiographic diagnosis can be difficult in patients with
eavily calcified valves (49). Differentiating severe bicuspid
ortic stenosis from severe unicuspid unicommissural aortic
tenosis can also be difficult, but this is particularly important
hen considering aortic valvuloplasty. In order to establish the
iagnosis, the valve must be visualized in systole in the
hort-axis view. During diastole, the raphe can make the valve
ppear trileaflet. In diastole, the orifice has a characteristic “fish
outhed” appearance. In the long-axis view, the valve often
as an eccentric closure line and there is doming of the
eaflets. If there is uncertainty in diagnosis, a transesopha-
eal echocardiogram can improve visualization of the leaf-
ets. In some instances, alternative cardiac imaging such as
ardiac magnetic resonance imaging or computer tomogra-
hy will help to confirm BAV anatomy, but more com-
only, these imaging modalities are used to visualize the
horacic aorta (Figs. 2A to 2D).
linical Course
lthough the clinical presentation of patients with BAV can
ary from severe valve disease in infancy to asymptomatic
alve or thoracic aortic disease in old age, symptoms
Figure 2 Images of the BAV and Aorta
(A) Transesophageal short-axis view of a bicuspid aortic valve (BAV). There is fusio
3-dimensional image of a BAV. The valve is seen in diastole with the characteristic
tic valve and aortic root. There is doming of the aortic valve leaflets (arrow) and d
nance image of the thoracic aorta. There is dilation of the ascending thoracic aortypically develop in adulthood. The clinical manifestations
elate to the function of the aortic valve (stenosis or
ncompetence), the aortopathy (dissection), and acquired
omplications such as endocarditis.
In childhood, BAV disease is commonly asymptomatic.
t is estimated that only 1 in 50 of children have clinically
ignificant valve disease by adolescence (50). Aortic stenosis
ue to a small valve orifice size can present in children with
AVs. Similarly, pure aortic incompetence secondary to a
rolapsed leaflet may occur in childhood. Earlier studies of
he unoperated clinical course in children were from the era
f cardiac catheterization. The unoperated clinical course
nd late outcomes in children with BAV, but without valve
ysfunction, have not been well studied.
Eventually during adulthood, the abnormal shear stress
eads to valve calcification and, in some, there is further
ortic root dilation (51,52). Estimates of the prevalence of
hese complications and outcomes have varied depending on
he era of the study, the cohort selected, and the method
sed to diagnose BAV (clinical exam vs. cardiac catheter-
zation vs. echocardiography). Two large recent series have
elped to better define the unoperated clinical course of
AV in the modern era (6,7) (Table 1). Estimates of late
ardiac events (medical and surgical complications) were
he right and left cusps. The arrow points to the raphe. (B) Transesophageal
outh appearance of the valve orifice. (C) Transthoracic long-axis view of the aor-
of the aortic sinus and ascending aorta. (D) Sagittal oblique cine magnetic reso-n of t
fish m
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Bicuspid Aortic Valve Disease June 22, 2010:2789–800pproximately 25% at a mean age of 44 years in the study
rom Toronto (7) and 40% at a mean age of 52 years in the
lmsted County study (6). Cardiac event rates were higher
f 1 or more of the following risk factors were present: age
30 years, moderate or severe aortic stenosis, and moderate
r severe aortic incompetence (Fig. 3). Importantly, in both
f these series, fatal events were rare. Most surgical proce-
ures involved aortic valve and aortic root replacements. In
he Olmsted County series (6), 27% of adults with BAV and
o significant valve disease at baseline required cardiovas-
ular surgery within 20 years of follow-up. Twenty-two
ercent of the patients in the Toronto cohort (7) required
Late Outcomes in Adults With BAV DiseaseTable 1 Late Outcomes in Adults With BAV
Patien
and N
Aortic Va
(n
Mean follow-up, yrs (range) 15
Mean age at baseline, yrs 3
Outcomes
Overall survival 90
Cardiac deaths
Aortic valve or ascending aorta surgery 2
Cardiovascular medical events 3
Aortic dissection
Hospital admission for heart failure
Endocarditis
Predictors of outcomes
Predictors of cardiac events
(medical and surgical)
Ag
Valve
*Adapted from Michelena et al. (6). Cardiovascular medical events
(dyspnea, syncope, anginal pain), stroke, and endocarditis. Surgical ev
and surgery of the thoracic aorta (for aneurysms, dissection, or coarcta
the aortic valve or ascending aorta, percutaneous aortic valvotomy, a
failure requiring hospital admission, or cardiac death. ‡Includes surge
BAV  bicuspid aortic valve.
N     642             639               296              41
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Figure 3 Frequency of Adverse Cardiac Events in Adults With B
Risk factors identified in this study included: age 30 years, moderate or severe
Reprinted, with permission, from Tzemos et al. (7).ntervention within 9 years of follow-up. In both studies,
ge was an important determinant of outcomes supporting
he notion held by many that eventually most patients with
AV would require some form of intervention.
ortic Stenosis
common complication of BAV disease is aortic stenosis.
lthough the fetus may survive with severe aortic stenosis
ecause the right heart can carry the full cardiac output in
tero, after birth these infants are at risk for cardiovascular
eterioration. Pre-natal diagnosis and treatment are now
ase
th BAV
ificant
sfunction
2)*
Patients With BAV
With a Spectrum of
Valve Function
(n  642)†
–25) 9 5 (2–26)
0 35 16
20 yrs 96 1% at 10 yrs
3 1%
‡ 22 2%
% NA
2 1%
2 1%
2%
yrs
eration
Age 30 yrs
Moderate or severe aortic stenosis
Moderate or severe aortic regurgitation
iac death, congestive heart failure, new cardiovascular symptoms
aortic valve surgery (aortic valve replacement, repair, or valvulotomy)
Adapted from Tzemos et al. (7). Primary cardiac events  surgery on
mplications (dissection or aneurysm development), congestive heart
oarctation of the aorta.
309              198
8 10
1 risk factor 18+3%
No risk factor 6+2%
> 1 risk factor 65+5%
years)
All subjects 25+2%
pid Aortic Valve Disease Stratified According to Risk Profile
regurgitation, and moderate or severe aortic stenosis.Dise
ts Wi
o Sign
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June 22, 2010:2789–800 Bicuspid Aortic Valve Diseaseossible (53). While not unique to BAV disease, myocardial
brosis can be seen in children with significant aortic
tenosis and is partially reversible after relief of the
bstruction (54,55). Children who present with aortic
tenosis in infancy have more severe disease and poor
utcomes (56 –58). Because there is often very little
alcification during childhood, balloon valvuloplasty is
he treatment of choice for severe aortic stenosis in this
ge cohort.
In the Joint Study of the Natural History of Congenital
eart Defects, one-third of the children in the cohort had
ncreases in catheterization gradients during the 4- to 8-year
ollow-up period (59). However, only a subgroup of children
ad follow-up, and the group of children with repeat catheter-
zations may not be representative of the entire BAV
opulation. In the follow-up study, children with baseline
eak left ventricular to aortic gradients50 mm Hg were at
isk for serious cardiac events at a rate of 1.2% per year (60).
owever, even in children with less valve involvement in
arly childhood, the disease can progress. Of the children
ith gradients 25 mm Hg, 20% required intervention
n follow-up. Similarly, in the United Kingdom cohort
20% of children with mild aortic stenosis at baseline
ad mild disease after 30 years of follow-up (61). Age was
he primary determinant of valvular disease progression.
In adults, the development of aortic stenosis is often due
o leaflet calcification, which occurs in a similar fashion to
hat seen in patients with trileaflet leaflet calcification. This
rocess is felt to be an active process, perhaps initiated by
ndothelial dysfunction and involving inflammation, li-
oprotein deposition, calcification, and ossification of the
ortic side of the valve leaflets (62). The folding and
reasing of the valves and the turbulent flow are felt to
ontribute to development of fibrosis and calcification (63).
he combination of these processes results in an accelerated
isease progression. Calcification is often present by 40
ears of age. In 1 series (64), more rapid progression in
ortic valve gradients occurred in patients with anteropos-
eriorly located cusps. In children, aortic valve disease is
ore significant in patients with right and noncoronary cusp
usion (65). However, not all studies have found this
ssociation, and the 2 large studies in adults have not
dentified leaflet orientation as a risk factor for late adverse
vents (6,7). This finding that valve orientation was not
redictive of outcomes in adults may reflect the modifying
ole of atherosclerosis risk factors and/or more advanced
egenerative process encountered in adults. Indeed, the
lmsted County study (6) identified a composite index of
alve degeneration, which incorporated valve thickening,
alcification, and mobility, that was an independent predic-
or of long-term cardiac events in a population of adults
ith no baseline valve dysfunction. The predictive role of
oth morphology and function in adults with BAV parallels
hat observed in series examining older adults with aortic
tenosis mostly of acquired basis (66–68). tortic Incompetence
n childhood, aortic incompetence can develop in the
etting of redundant or prolapsing cusps, endocarditis, or
fter balloon valvuloplasty (69,70). With age, aortic incom-
etence may also develop secondary to dilation of the
scending aorta. Although adults with BAV often have
ome degree of aortic regurgitation, the actual prevalence of
ure aortic incompetence has varied, with some suggesting
t is rare and others suggesting that it is common (3,71,72).
n 1 large surgical series, 13% of surgically excised valves at
he time of aortic valve replacement were for pure aortic
ncompetence (9). In the Olmstead county echocardio-
raphic study of asymptomatic adults (6), 47% had some
egree of aortic incompetence at baseline; however, inter-
entions for severe aortic incompetence were relatively
ncommon, occurring in only 3% of the cohort during
ollow-up. In the Toronto study (7), 21% of the population
ad moderate or severe aortic incompetence at baseline;
owever, only 6% had an intervention for symptomatic
ortic incompetence or progressive left ventricular dysfunc-
ion. Despite variations in prevalence, moderate or severe
ortic incompetence is clinically important and is an inde-
endent predictor for late adverse cardiac events.
ortopathy and Aortic Dissection
ortic root dilation has been documented in childhood,
uggesting that this process begins early in life (73–75).
urthermore, children with BAV have greater increases in
ortic dimensions than do children with trileaflet valves
73). In both children and adults, progressive dilation of the
orta is more common in patients with larger aortas at
aseline (76–78). In BAV disease, the aortic annulus, sinus,
nd proximal ascending aorta are larger than those found in
dults with trileaflet valves (79–81). These differences
ersist even after adjusting for blood pressure (systolic and
iastolic), peak aortic velocities, and left ventricular ejection
ime (79). Our group reported a prevalence of aortic sinus
ilation of 28% (mean age 35  16 years), and after 9 years
f follow-up, the prevalence had increased to 45% with a
edian increase in the aortic sinus dimension of 0.2
m/year (7). In the Olmsted County study (6), the preva-
ence of ascending aorta dilation (40 mm) was 15% and in
he subset of patients with repeat measurements, the prev-
lence increased to 39% at study completion. Dilation of the
scending aorta was an independent risk factor for ascend-
ng aorta surgery. Although there are a number of risk
actors associated with dilation of the ascending aorta
ncluding increased systolic blood pressure, male sex, and
ignificant valve disease, the most important variable is
ikely age (7,79,82,83). Aortic root size is shown to be
elated to valve morphology and the presence of significant
alve disease (82,84). Specifically, the increased stroke
olume from aortic incompetence is felt to result in stress on
he diseased aorta and subsequent aortic dilation (82,85,86).
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Bicuspid Aortic Valve Disease June 22, 2010:2789–800hanges in the aortic media during pregnancy may pre-
ispose to subsequent aortic dilation, but this has not been
onfirmed by prospective studies.
The most feared complication is aortic dissection, pri-
arily due to the high associated mortality rate; however,
he actual incidence of this complication is debated. Al-
hough the prevalence varies depending on the cohort
tudied, a pooled estimate of cases of dissection associated
ith BAV was 4% (4,87–89). Recent studies suggest a
ower risk. In the Toronto series (7), the prevalence of
issection was 0.1% per patient-year of follow-up, and in
he Olmsted County study (6), there were no cases of
issection. Despite the low rates of dissection, the increased
revalence of BAV disease relative to Marfan syndrome
ake dissections due to BAV equal to or more common
han dissections due to Marfan syndrome (90). Dissection
n BAV, when it occurs, typically involves the ascending
orta, but involvement of the descending aorta has been
eported in older patients (2). Distal aortic disease may be
elated to BAV or may be secondary to other risk factors
ommonly found in older individuals. Although dissection is
ore common in patients with dilated aortas, there are reports
f dissection in normal-sized aortic roots and after valve
eplacement (91). Risk factors for dissection have included
ortic size (92,93), aortic stiffness (94), male sex (95), family
istory (96), and the presence of other lesions such as coarc-
ation of the aorta (95) or Turner syndrome (97).
ndocarditis
ndocarditis can lead to valve perforation or destruction and
esult in severe aortic incompetence. When this occurs
cutely, it is poorly tolerated. Endocarditis risk, based on
Figure 4 Survival in Adults With Bicuspid Aortic Valve With No
Dashed line represents subjects with bicuspid aortic valve disease compared with
Reprinted, with permission, from Michelena et al. (6).arlier case series, was estimated to range between 10% and
0% (3). However, high rates were likely due to reporting
ias in earlier studies, and more recent estimates of the
ncidence of endocarditis are much lower at 2% or 0.3%/year
6,7). Because the risk of endocarditis is felt to be low, the
CC/AHA practice guidelines no longer suggest bacterial
ndocarditis prophylaxis in patients with straightforward
AV disease, except in patients with a prior history of
ndocarditis (98). Because these guidelines are a significant
eparture from the prior recommendations, physicians
nd/or patients accustomed to the routine use of endocar-
itis prophylaxis may be hesitant to apply these new
ecommendations.
urvival
espite these complications, 2 large series have con-
rmed that in the current era, life expectancy in adult
atients with BAV disease is not shortened when com-
ared with the general population. In asymptomatic
dults with BAV with a spectrum of valve function, the
0-year survival was 96  1% (7), and in asymptomatic
dults with BAV without significant valve dysfunction,
he 20-year survival was 90  3% (6) (Fig. 4).
urveillance
n order to follow disease progression, serial transthoracic
chocardiograms should be performed in all patients. At a
inimum, annual cardiac imaging is recommended for
atients with significant valve lesions or those with aortic
oot diameters 40 mm. In those patients without signif-
cant valve lesions and aortic roots diameters 40 mm,
ificant Aortic Valve Dysfunction
e- and sex-matched control population (solid line).Sign
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June 22, 2010:2789–800 Bicuspid Aortic Valve Diseaseardiac imaging every 2 years may be adequate (48,50).
ortic root size should be referenced to body surface area,
specially in patients where body size is important, such as
omen and patients with Turner syndrome. An aortic sinus
imension of 2.1 cm/m2 is considered the upper limit of
ormal (99,100). Complete imaging of the thoracic aorta
hould be performed periodically for surveillance. Because
omputer tomography scans are associated with significant
adiation exposure, they should only be performed in this
oung population if needed and if other imaging modalities
re not available. Other parameters, such as compliance of
he aorta, can be measured with echocardiography or mag-
etic resonance imaging. Aortic elasticity is reduced in
atients with BAV and aortic regurgitation and, in the
uture, these physiologic measures may have a role in risk
tratification (94,101). Measures of systemic endothelial
ysfunction, such as brachial flow-mediated vasodilation to
yperemia and carotid-femoral pulse wave velocity, have
een shown to be abnormal in patients with BAV, suggest-
ng that BAV perhaps represents a generalized vascular
rocess (102).
In the future, biomarkers may be useful for assessment of
he valve, the response of the ventricle to the valve disease,
nd the aortic root disease. For example, in degenerative
ortic valve disease, brain natriuretic peptide has been
hown to be prognostically important (103–105). Serum
arkers such as matrix metalloproteinase, aminoterminal
ropeptide of type III collagen, fibrinogen, and markers of
nflammation are elevated in subjects with abdominal aortic
neurysms (106). Little information is available on these or
ther serum biomarkers in BAV disease. We have demon-
trated that ascending aortic dilation was associated with
ncreased serum matrix metalloproteinase 2 in young men
ith nonstenotic BAV (102). The clinical utility of these
nd other serum markers requires further study.
edical Therapy
t a minimum, high blood pressure should be aggressively
reated in patients with BAV disease. In Marfan-associated
ortopathy, treatment with beta-blockers to slow the rate of
rogression is the standard of care at many centers, although
ebate exists about their effectiveness (107,108). Some
linicians have extrapolated this practice to the treatment of
ortopathy associated with BAV disease. The ACC/AHA
uidelines for the management of adult congenital heart
isease and guidelines for the management of patients with
alvular heart disease suggest that it is reasonable to use
eta-blockers in this population (Class IIa recommenda-
ion) (48,109). There are emerging data in animal models
nd in 1 small study in humans supporting the use of
ngiotensin II receptor blockers to decreased aortic root
ilation in Marfan syndrome (110,111). Whether these
gents will have a role in BAV aortopathy has not yet been
emonstrated. Finally, long-term vasodilator therapy in sAV disease with aortic regurgitation is only recommended
f there is concomitant systemic hypertension (48).
The relationship between risk factors for atherosclero-
is and the development and progression of degenerative
ortic valve disease has been well studied (112). However,
he role of treatment with cholesterol-lowering agents is
nresolved. Although some studies (113,114) have dem-
nstrated slowing of the progression of aortic valve
isease, 1 large prospective randomized trial (115) found
hat treatment did not stop disease progression in calcific
ortic stenosis. Two additional prospective studies ad-
ressing this issue are still in progress. The use of lipid
owering agents specifically in young patients with BAV has
ot been studied, and the current ACC/AHA guidelines for
he management of patients with valvular heart disease do not
ndorse the use of statins to slow the degenerative process in
his population (50).
nterventions
hen rheumatic disease is excluded, a significant portion of
dults undergoing surgery for aortic valve disease will have a
ongenitally malformed valve (116). In many cases, indica-
ions for surgery are similar to that in patients with tricuspid
alve disease or “degenerative aortic valve disease” (50).
owever, some features are unique to this population and
equire consideration.
During childhood, insertion of a prosthetic valve is
uboptimal because of the continuing growth of the child.
ortunately, at this stage, the aortic valve is usually not
alcified and valvuloplasty can successfully disrupt the com-
issural fusion and relieve obstruction. Valvuloplasty is the
nterventional strategy of choice in children and in some
oung adults with BAV and aortic stenosis. In the current
ra, surgical valvotomy has been replaced by balloon valvu-
oplasty. Thresholds for interventions differ in part because
alvuloplasty is felt to be a relatively low-risk procedure and
ecause the population is somewhat different than the adult
ith aortic stenosis. Symptomatic aortic stenosis is an
ndication for intervention, similar to standard indications
or degenerative trileaflet valve disease. However, in the
ediatric setting, indications include children with peak-to-
eak gradients 50 mm Hg who develop ST- or T-wave
hanges at rest or with exercise or who are interested in
articipating in athletics. An additional indication in-
ludes asymptomatic children with peak-to-peak gradi-
nts 60 mm Hg (50,117). Mid-term results after
alloon valvuloplasty are good at experienced centers
118 –120). In instances when aortic incompetence de-
elops after balloon valvuloplasty, aortic valve replace-
ent may be necessary.
In adulthood, aortic valve replacement is the most
ommon intervention for either aortic valve stenosis or
ncompetence, and valvuloplasty is rarely performed (7).
urgery for BAV disease occurs at an earlier age than
urgeries for degenerative tricuspid aortic disease (116).
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Bicuspid Aortic Valve Disease June 22, 2010:2789–800n the Olmsted County series (6), the average age for
AV surgery was 40  20 years versus 67  16 years for
atients with tricuspid aortic valve. The usual surgical
ptions include valve replacement (bioprosthetic or me-
hanical valves), Ross operations (native pulmonary valve
oved to the aortic position and a homograft placed in
he pulmonary position), or valve repair for those with
ortic incompetence (121). Indications of interventions
or aortic stenosis or incompetence are similar to those
escribed for tricuspid aortic valve disease in the ACC/
HA guidelines for the management of patients with
alvular heart disease (50). BAV disease involves younger
atients and involves both the valves and the great
rteries; therefore, surgical decision making is more
omplicated. Approximately 30% of adults undergoing
ortic valve replacement will also need aortic root surgery
7). Because of the risk of further root dilation, many
urgeons consider reinforcing or replace the ascending
orta at the time of valve surgery (91). The dimension of
he aortic root felt to require surgical attention has varied
ver time, and in many cases, this threshold value for
ntervention is institution- and surgeon-specific. The
urrent guidelines suggest that a cutoff of 5.0 cm be used
or intervention or 4.5 cm if the surgery is otherwise
eing performed for valve indications (50). Although not
ncorporated into current guidelines, aortic size relative
o body size may be a better method to define the
igh-risk group requiring surgery (92). In addition, the
uidelines suggest that changes in root size more than 0.5
m/year are an indication for root replacement. Average
nnual changes in ascending aorta in patients with BAV
ary between 0.2 to 1.2 mm/year (73,82,122–124). Be-
ause of limitations with the current data, some have
uestioned the basis for these recommendations and have
uggested that thresholds for intervention should be
econsidered (89).
In regard to valve surgery, there is controversy regarding
he use of the Ross procedure and the use of valve repairs in
his population. Abnormalities of the media are seen in both
he aorta and the pulmonary artery in BAV disease
17,18,22). Intrinsic abnormalities in the wall of the pul-
onary artery (neoaorta) may contribute to progressive
eoaortic root dilation and/or aortic regurgitation when the
ulmonary root is placed in the systemic position (125).
ecause of this potential late complication, some do not
dvocate the use of the Ross operation in patients with BAV
isease. Despite good mid-term results with valve-sparing
perations and the well-described progression of disease,
ome experts believe that leaving behind the abnormal BAV
s ill-advised. Therefore, the optimal surgical approach for
atients with BAV remains to be defined.
regnancy
uring pregnancy there are changes in hemodynamics as
ell as changes in the aortic media, and therefore, women (ith BAV and significant aortic stenosis and/or dilated
ortic roots are at risk for complications during preg-
ancy. Recent studies from our center and others suggest
hat the risk of adverse pregnancy events in women with
evere aortic stenosis is less than previously described.
ven though this group of women continue to represent
high-risk group for maternal and fetal morbidity, their
verall mortality risk is likely 1% based on recent
tudies (126 –128). In rare instances, women will develop
rogressive symptoms during pregnancy and require ei-
her valvuloplasty or valve surgery. Both interventions can
e performed during pregnancy, but are associated with
oth maternal and fetal risks and should be performed
nly when necessary. Although the mechanisms that
redispose some women to deteriorate during pregnancy
re not completely understood, in a preliminary study, we
eported that women with moderate and severe aortic
tenosis who deteriorated in the antepartum period failed
o increase left ventricle twist (129). Although pregnancy
an be successfully completed in most instances, aortic
urgery may be required early after pregnancy in some
omen with severe aortic stenosis (127,130). Pregnancy
tself seems to accelerate the need for surgery post-
artum in women with moderate or severe aortic stenosis,
erhaps by affecting the ability of the left ventricle to
dapt to the fixed outflow obstruction (130). It is there-
ore important that women be counseled about both the
isk of pregnancy and the potential for late complications.
dditionally, guidelines suggest that women with BAV
nd significant aortopathy (ascending aorta diameter
4.5 cm) “should be counseled against the high risk of
regnancy” (48). What this counseling would entail and
he evidence underlying this recommendation is not clear
s the risk of pregnancy in a woman with BAV and a
ilated root has not been systematically examined.
xercise
ecause BAV can affect children and young adults, exercise
uidelines are often important for this group of patients.
owever, there are little data available to support recom-
endations regarding exercise in subjects with BAV. In
hildren with congenital severe aortic stenosis, for instance,
udden death can occur during exercise (131–133). The
ask Force on Exercise in Patients with Heart Disease
ecommends that athletes with severe aortic stenosis or
evere aortic incompetence with left ventricular dilation (left
entricular dimensions 65 mm) should not participate in
ompetitive athletics. Athletes with or without aortic valve
isease who have dilated aortic roots (45 mm) are advised
o only participate in low-intensity competitive sports. No
estrictions exist for those with BAV with no significant
alve dysfunction or aortic root/ascending aorta dilation
40 mm) (134,135).
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June 22, 2010:2789–800 Bicuspid Aortic Valve Diseaseuture Directions
hile recent cohort studies have helped to improve our
nderstanding of the complication rate in adults with BAV,
ontinued cohort studies remain important and ideally
hould begin in childhood. Understanding the disease from
hildhood to adulthood will help to define late survival
ccurately, identify high-risk groups earlier, improve timing
f interventions, and accurately study outcomes after inter-
ention. In addition to the traditional clinical and echocar-
iographic predictors of adverse outcomes discussed in this
eview, other prognostic markers of disease will likely
ecome important such as serum markers, new cardiac
maging measures, and genetic markers. Apart from treat-
ng endocarditis, no medical therapy has proven benefi-
ial, but randomized clinical trials are currently underway
ith the aim of improving outcomes by modifying valve
nd aortic root progression. Furthermore, with advances
n our understanding of the process of valve degeneration
nd aortic root dilation, new potential therapeutic targets
ill be identified.
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